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OBJECTIVE: To estimate the relationship between maternal methadone dose and the incidence of neonatal abstinence syndrome (NAS).
METHODS:
We performed a retrospective cohort study of pregnant women treated with methadone for opiate addiction who delivered a live-born neonate between 1996 and 2006. Four dose groups, based on total daily methadone dose, were compared (≤80mg/d, 81-120mg/d, 121-160mg/d, and >160mg/d). The primary outcome was treatment for NAS. Symptoms of NAS were objectively measured using the Finnegan scoring system and treatment was initiated for a score of >24 during the prior 24 hours.
RESULTS: 330 women treated with methadone and their 388 offspring were included.
Average methadone dose at delivery was 116.6 ±49.7mg/d (range 20-340mg/d). Overall, 68% of infants were treated for NAS. Among infants exposed to methadone doses of ≤80mg/d, 81-120mg/d, 121-160mg/d, and >160 mg/d, treatment for NAS was initiated for 68%, 63%, 70%, and 73% of neonates, respectively (p=0.48). The rate of maternal illicit opiate abuse at delivery was 26%, 28%, 19%, and 11%, respectively (p=0.04).
CONCLUSION:
No correlation was found between maternal methadone dose and rate of NAS.
However, higher doses of methadone were associated with decreased illicit opiate abuse at delivery. (9) Of eight published studies, to our knowledge, which include a "low" dose group of < 30 mg/d 78% report a positive correlation between maternal methadone and NAS.(6)(7)(8)(9)(10)(11)(12)(13) Presently, methadone maintenance programs for pregnant women, such as ours, use significantly higher doses to prevent withdrawal. Five out of six (83%) more recent published studies which use a 7 higher cutoff (< 50 mg/d or above) to define the "low" dose group report no such association. (14) was not required for this study.
RESULTS
We analyzed outcomes of 330 opiate-addicted women on methadone treatment who had 386 pregnancies from September 1996 to June 2006. Two women had twins, thus our study included 388 neonates. The gestational age at birth was < 32 weeks for 19 neonates (range 27-31 weeks) excluded from the study. Maternal demographic characteristics are presented in Table 2 .
Only race differed among dose groups (p = .04). Caucasian women were on higher mean doses of methadone (122.9 ± 50.7 mg/d) when compared to non-Caucasian women (103.5 ± 44.9 mg/d, p < .001). Psychiatric medications were prescribed to 27% of women in the methadone maintenance program and 23% of those women were taking more than one psychiatric medication (data available for 288 pregnancies). The proportion of women in each dose group using prescription psychiatric drugs was not significantly different (p = .39) but prescription benzodiazepine use (mainly clonazepam) was more common among women on higher doses (p = .01). (Figure) .
The rate of NAS was compared between methadone dose groups for selected subpopulations of women (Table 4) . NAS was more common among neonates born to women who were initially stabilized on methadone during pregnancy but the difference was not statistically significant (p = .18). There was no difference in the incidence of NAS between methadone dose groups for either neonates born to women who conceived on methadone or those who were born to women initially stabilized on methadone during pregnancy. Likewise, these was no difference in the incidence of NAS between dose groups for the subpopulations of women abusing illicit opiates at delivery, women whose UDS was negative for illicit opiate abuse at delivery, women who delivered prematurely, and those who delivered at term.
Lastly, we also investigated other variables predictive of NAS (Table 6 ; online only).
Through a univariate analysis, preterm birth, tobacco use, and illicit opiate and cocaine abuse at delivery increased the risk for NAS (Table 5 ; online only). However, after adjusting for confounding, only preterm birth (adjusted OR 3.0, 95% CI 1.4 -6.1) remained predictive of NAS. Tobacco use had a trend towards increased risk for NAS (adjusted OR 2.2, 95% CI 0.98 -5.0).
DISCUSSION
The incidence of NAS in our population was 68% and is well within the literature's reported range of 30% to 81%.(9)(22) Even among neonates born to women prescribed the lowest methadone dose, NAS required treatment in more than half of neonates. In our population, the incidence of NAS requiring pharmacologic treatment does not reflect maternal methadone use in a dose dependent fashion. Furthermore, higher doses of methadone were associated with decreased maternal illicit opiate abuse at delivery.
There is strong physiologic evidence to support our policy of liberal dose increases to decrease maternal withdrawal symptoms. First, physiologic changes throughout pregnancy alter the pharmacokinetics and pharmacodynamics of methadone. Plasma volume is increased leading to an increased volume of distribution. The fraction of oral methadone absorbed is decreased, the half life of methadone decreased (27) secondary to increased hepatic clearance (28)(29) The concentration of methadone crossing the placenta determined by gestational agedependent passive diffusion, P-glycoprotein efflux, and metabolism by placental aromatase.
(33)(34)(35)(36) The fetal concentration is then modified by hepatic metabolism, a process which is also gestational age dependent. Ultimately, the expression of opioid withdrawal is dependent on the final neonatal methadone concentration and its interplay with the central nervous system (also gestational age dependent [21] ). Even the exact relationship between neonatal methadone levels at birth is unclear (17)(22)(24)(37)(38) and total opioid exposure (methadone plus other illicit opiate abuse) should be factored in as a confounder. Given the complex relationship between the mechanisms that determine neonatal dose and expression of NAS, it unlikely an individual woman's methadone dose will reliably predict neonatal outcome.
Most of the women in our study had one or more exposures to tobacco, alcohol, other Our findings provide compelling evidence that no correlation exists between maternal methadone dose and rate of NAS. Reducing maternal methadone doses to theoretically lower the risk for NAS appears unwarranted. Instead, the goal of the clinician should be to administer doses of methadone that adequately control maternal withdrawal symptoms and reduce drug cravings. In the future, a randomized, double blinded study to validate our results in which in one group women are restricted to a certain dose while the ones in the other group aren't would be ideal. There may be ethical concerns over restricting dose and possibly subjecting both the mother and fetus to withdrawal as this would constitute detoxification. In our opinion, an adequately powered prospective trial with both the physician prescribing methadone and the pediatrician blinded to dose, an objective measurement of NAS, and controlling for known confounders would probably be a viable alternative. 
